IAI Overview
- Status
-
Private
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$100K
- Investors
-
1
IAI General Information
Description
Developer of immune repertoire sequencing and analysis technologies designed to redefine the treatment of heterogeneous diseases through mechanistic insights. The company's platform utilizes advanced computational models to analyze B-cell and T-cell receptor sequences at scale, transforming immune system data into a queryable digital representation of immune memory to identify mechanistic biomarkers, enabling pharmaceutical companies and clinical researchers to redefine heterogeneous chronic diseases like autoimmunity and neuropsychiatric disorders, thereby improving clinical trial outcomes and accelerating diagnostic accuracy.
Contact Information
Corporate Office
- Rahway, NJ
- United States
Corporate Office
- Rahway, NJ
- United States
IAI Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | 01-Jan-2026 | $100K | Completed | Startup |
IAI Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Merck Digital Sciences Studio | Accelerator/Incubator |
IAI FAQs
-
Where is IAI headquartered?
IAI is headquartered in Rahway, NJ.
-
What industry is IAI in?
IAI’s primary industry is Biotechnology.
-
Is IAI a private or public company?
IAI is a Private company.
-
What is IAI’s current revenue?
The current revenue for IAI is .
-
How much funding has IAI raised over time?
IAI has raised $100K.
-
Who are IAI’s investors?
Merck Digital Sciences Studio has invested in IAI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process